drugset

drugset / Trial / NCT00440492

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

NCT00440492 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

Timeline

Start: 2006-12
Primary completion: —
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GIRIPLADIB	Small molecule	—	—

Indications